Spiral Therapeutics, a South San Francisco, CA-based clinical-stage company focused on delivering therapies for inner ear disorders, raised an undisclosed amount in new financing.
The round was led by Esperante Ventures and Ferring Ventures SA. As part of this financing, Spiral added Dean Slagel, Managing Director of Esperante Ventures, to its Board of Directors.
The company intends to use the funds to accelerate its development efforts to treat inner ear disorders, including the collection of additional clinical data for its lead program SPT-2101 for Meniere’s Disease, and to advance its hearing loss pipeline.
Led by CEO Hugo Peris, Spiral Therapeutics is a clinical-stage company focused on delivering therapies for inner ear disorders. Its novel drug delivery platform allows for minimally invasive, precise and durable exposure of drugs to the cochlea. The company works for a therapeutic pipeline with focus on hearing loss and balance disorders. Spiral’s lead program, SPT-2101, is a sustained-release steroid formulation for the treatment of inner ear inflammation.
Commenting on the news, Hugo Peris said: “This fresh round of investment reflects the confidence in our unique drug delivery approach and technology, and strengthens our resolve to innovate in the field of neurotology. With the recent acquisition of Otonomy assets and our growing therapeutic pipeline, we are positioning Spiral as a forerunner in the field.”
FinSMEs
30/08/2023